Novozymes

NSIS.B · Nasdaq Copenhagen · DKK

kr 416.00+0.73%+kr 3.00

Close · October 2, 2026

At a glance

Revenue growth: +8.45%; 2025 vs 2024
Net income growth: +90.84%; 2025 vs 2024
Net margin: 14.0%; 2024: 8.0%

Financial data

Amounts in millions of EUR; per-share values in EUR; shares in millions.

Balance sheet · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total assets	16,633	16,523	16,349	16,303	16,401	15,057	15,196	—	15,252	—	3,809	3,824
Current assets	2,081	2,046	1,983	1,956	2,052	1,946	1,879	—	1,808	—	1,269	1,265
Cash and equivalents	309	327	275	281	328	250	280	—	261	—	150	157
Short-term investments	4.9	2.2	20.3	—	37.2	7.0	—	—	—	—	—	—
Receivables	931	924	915	905	887	959	863	—	827	—	583	586
Inventory	836	793	772	742	800	730	721	—	687	—	487	520
Net property, plant and equipment	3,149	3,055	2,998	2,869	2,834	2,915	2,968	—	2,866	—	1,654	1,699
Goodwill	6,310	6,274	6,193	6,201	6,154	5,534	5,605	—	5,571	—	265	269
Other intangible assets	4,810	4,865	4,896	4,972	5,053	4,343	4,419	—	4,692	—	343	342
Long-term investments	14.9	16.2	17.5	20.6	20.2	22.7	24.0	—	25.7	—	27.5	28.3
Current liabilities	1,197	1,222	2,741	1,212	1,171	1,170	1,088	—	1,631	—	974	834
Accounts payable	366	364	421	298	302	318	423	—	346	—	217	196
Long-term debt	2,639	2,729	1,145	2,805	2,975	1,269	1,366	—	1,073	—	581	593
Total debt	3,068	3,212	—	3,108	3,322	1,699	—	—	—	—	—	—
Total liabilities	5,478	5,604	5,494	5,559	5,658	3,827	4,020	—	4,247	—	1,884	1,829
Total equity (incl. minority)	11,155	10,920	10,855	10,744	10,743	11,231	11,176	—	11,005	1,926	1,925	1,995
Retained earnings	11,273	11,091	11,159	11,039	11,037	11,204	11,032	—	10,900	—	1,845	1,851
Minority interest	—	—	0.0	—	0.0	0.0	—	—	1.5	—	50.0	54.4